Our mission is to explore the possibility of conducting phase 3 clinical trials of PM-012 for the treatment of dementia and Alzheimer's disease simultaneously in both Korea and the United States! We're thrilled that Mediforum will now be listed on NASDAQ,
Aducanumab, the latest drug approved by the FDA for the treatment of Alzheimer'sis estimated to cost $56,000 annually. According to the New York Times, "There’s little evidence that the drug, Aduhelm, slows the progression of dementia, but the Food and Dr
Brain One is a naturally derived supplement made from a combination of extracts to improve memory %26 concentration. Combining the natural compounds with four-year-aged Korean ginseng boosts the immune system, enhances platelet count, and increases blood
